跳转至内容
Merck
CN

C3350000

阿糖胞苷

European Pharmacopoeia (EP) Reference Standard

别名:

胞嘧啶 β-D-呋喃阿拉伯糖苷, (β-D-阿拉伯呋喃糖基)胞嘧啶, Ara-C, 胞嘧啶阿拉伯糖苷, 阿拉伯糖胞嘧啶, 阿糖胞嘧啶, 阿糖胞苷

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C9H13N3O5
CAS号:
分子量:
243.22
Beilstein:
89175
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24

等级

pharmaceutical primary standard

API类

cytarabine

制造商/商品名称

EDQM

应用

pharmaceutical (small molecule)

格式

neat

储存温度

2-8°C

SMILES字符串

NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O

InChI

1S/C9H13N3O5/c10-5-1-2-12(9(16)11-5)8-7(15)6(14)4(3-13)17-8/h1-2,4,6-8,13-15H,3H2,(H2,10,11,16)/t4-,6-,7+,8-/m1/s1

InChI key

UHDGCWIWMRVCDJ-CCXZUQQUSA-N

正在寻找类似产品? 访问 产品对比指南

一般描述

本品按现行药典规定交付。所有为支持本产品而提供的信息,包括SDS和任何产品信息单均由药典颁发机构制定并发布。如需进一步信息和支持,请访问现行药典网站。

应用

阿糖胞苷EP参考标准品的预期用途是欧洲药典规定的实验室测试。

生化/生理作用

阿糖胞苷复合到 DNA 中后,可通过与导致 DNA 断裂的拓扑异构酶 I 形成可裂解复合物而抑制 DNA 的复制,但不会抑制 RNA 的合成。抗白血病制剂。

包装

本品按照现行药典要求提供。有关当前单位数量,请见EDQM 参考目录

其他说明

可能适用相应的销售限制。

象形图

Health hazardExclamation mark

警示用语:

Warning

危险声明

危险分类

Repr. 2 - Skin Sens. 1

WGK

WGK 3


Choose from one of the most recent versions:

分析证书(COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Erinn S Gideons et al.
Proceedings of the National Academy of Sciences of the United States of America, 111(23), 8649-8654 (2014-06-10)
Ketamine is an NMDA receptor (NMDAR) antagonist that elicits rapid antidepressant responses in patients with treatment-resistant depression. However, ketamine can also produce psychotomimetic effects that limit its utility as an antidepressant, raising the question of whether the clinically tolerated NMDAR
M R Sapienza et al.
Leukemia, 28(8), 1606-1616 (2014-02-08)
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare disease of controversial origin recently recognized as a neoplasm deriving from plasmacytoid dendritic cells (pDCs). Nevertheless, it remains an orphan tumor with obscure biology and dismal prognosis. To better understand the
H Yang et al.
Leukemia, 28(6), 1280-1288 (2013-11-26)
Blockade of immune checkpoints is emerging as a new form of anticancer therapy. We studied the expression of programmed death ligand 1 (PD-L1), PD-L2, programmed death 1 (PD-1) and cytotoxic T lymphocyte-associated antigen 4 (CTLA4) mRNA in CD34+ cells from
Fazila Asmar et al.
Oncotarget, 5(7), 1912-1925 (2014-04-12)
MiR34A, B and C have been implicated in lymphomagenesis, but information on their role in normal CD19+ B-cells (PBL-B) and de novo diffuse large B-cell lymphoma (DLBCL) is limited. We show that in normal and activated B-cells miR34A-5p plays a
Robert J Vanner et al.
Cancer cell, 26(1), 33-47 (2014-06-24)
Functional heterogeneity within tumors presents a significant therapeutic challenge. Here we show that quiescent, therapy-resistant Sox2(+) cells propagate sonic hedgehog subgroup medulloblastoma by a mechanism that mirrors a neurogenic program. Rare Sox2(+) cells produce rapidly cycling doublecortin(+) progenitors that, together

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门